MYSZ

Business Context and Reporting Period

Company: TopSpin Medical, Inc. (Note: Input metadata referenced "My Size, Inc.", but the filing text identifies the registrant as TopSpin Medical, Inc.)
Reporting Period: Quarter ended June 30, 2010 (Unaudited)
Status: Development Stage Company; Shell Company
Operations: The Company suspended operational activities in October 2008 due to financial constraints and discontinued intellectual property development in January 2010. It has generated no revenue since inception. On July 12, 2010, the Company filed a voluntary petition for relief under Chapter 11 of the U.S. Bankruptcy Code.

Key Financial Metrics

Note: Financial statements are presented in NIS (Israeli New Shekels) in thousands. Approximate USD conversions provided in text: Cash ~$31k; Net Loss (6mo) ~$189k; Operating Cash Flow (6mo) ~$543k.

Material Changes vs. Prior Period

• Cash Position: Cash and cash equivalents decreased significantly from NIS 1,002,000 at December 31, 2009, to NIS 121,000 at June 30, 2010.
• Liabilities: Current liabilities increased from NIS 2,488,000 to NIS 2,934,000, driven primarily by a new loan from a related party (Medgenesis Partners Ltd.) of NIS 1,101,000.
• Expenses: General and administrative expenses decreased to NIS 672,000 for the quarter ended June 30, 2010, compared to NIS 1,099,000 in the same period in 2009, reflecting the suspension of operations and reduced staff.
• Financing: Financing income/expense shifted from a gain of NIS 398,000 in Q2 2009 to an expense of NIS 42,000 in Q2 2010.

Outlook, Risks, and Contingencies

• Chapter 11 Bankruptcy: The Company filed for Chapter 11 protection on July 12, 2010. The reorganization plan seeks to convert the Medgenesis loan into common stock and execute a reverse stock split. Failure of this process may lead to liquidation.
• Liquidity Risk: The Company has substantial doubt about its ability to continue as a going concern. It holds only NIS 121,000 in cash and relies on the remaining balance of the Medgenesis loan to fund bankruptcy proceedings for the next 12 months.
• Delisting Risk: The Tel Aviv Stock Exchange (TASE) notified the Company on July 18, 2010, that its shares would be moved to the preservation list effective July 19, 2010, due to equity falling below NIS 2,000.
• Internal Controls: Management concluded that disclosure controls and procedures were ineffective as of June 30, 2010, citing a material weakness due to the finance department being downsized to a single employee.
• Contingent Liabilities: The Company has an obligation to pay royalties to the Office of the Chief Scientist of Israel totaling approximately NIS 17,985,000, contingent on future sales (which have not occurred).

Investor Verification Checklist

• Bankruptcy Status: Verify the current status of the Chapter 11 case (Case No. 10-12213) in the U.S. Bankruptcy Court for the District of Delaware and the likelihood of the reorganization plan's approval.
• Related Party Loan Terms: Confirm the terms of the Medgenesis loan, specifically the interest rate escalation to 12% if not repaid and the conditions for conversion to equity.
• Going Concern Assessment: Review the Company's ability to raise additional capital to redeem long-term liabilities, as current cash reserves are insufficient for long-term operations.
• Stock Exchange Status: Confirm the implications of the TASE preservation list status on the liquidity and tradability of the Company's shares.
• Internal Control Remediation: Assess the Company's plan to remediate the material weakness in internal controls caused by the lack of financial personnel.